Shock and cerebral infarct after rifampin re-exposure in a patient infected with human immunodeficiency virus.
Martínez
E
E
Section of Infectious Diseases, Hospital de Galdakao, Vizcaya, Spain.
Collazos
J
J
Mayo
J
J
D000328:Adult; D000707:Anaphylaxis / Q000139:chemically induced*; D000904:Antibiotics, Antitubercular / Q000008:administration & dosage / Q000009:adverse effects*; D000995:Antitubercular Agents / Q000008:administration & dosage; D002544:Cerebral Infarction / Q000139:chemically induced*; D004342:Drug Hypersensitivity / Q000209:etiology*; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage; D008297:Male; D011718:Pyrazinamide / Q000008:administration & dosage; D012293:Rifampin / Q000008:administration & dosage / Q000009:adverse effects*; D014397:Tuberculosis, Pulmonary / Q000150:complications / Q000188:drug therapy*
D000904:Antibiotics, Antitubercular; D000995:Antitubercular Agents; D011718:Pyrazinamide; D007538:Isoniazid; D012293:Rifampin